Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Diaceutics ( (GB:DXRX) ) has issued an announcement.
Diaceutics has reported that the trustees of its Global 2020 Employee Benefit Trust have been purchasing ordinary shares on behalf of several senior managers under the company’s UK and Global Share Incentive Plan, with these purchases set to continue monthly until further notice. In line with the plan’s terms, Diaceutics has matched employee purchases on a 1:1 basis, issuing 6,486 new shares to its UK trust to satisfy matched awards, bringing the total number of shares in issue to 84,912,435 and providing an updated reference figure for investors monitoring their holdings under UK disclosure rules.
The most recent analyst rating on (GB:DXRX) stock is a Hold with a £142.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Spark’s Take on GB:DXRX Stock
According to Spark, TipRanks’ AI Analyst, GB:DXRX is a Neutral.
Diaceutics’ strong revenue growth and positive corporate events are overshadowed by challenges in profitability, cash flow, and bearish technical indicators. The stock’s valuation is also concerning due to negative earnings.
To see Spark’s full report on GB:DXRX stock, click here.
More about Diaceutics
Diaceutics PLC is a technology and solutions provider to the global pharma and biotech industry, specialising in the commercialisation of precision medicines. Through its DXRX – The Diagnostics Network platform, the company delivers data analytics, scientific and advisory services to help ensure patients receive the right diagnostic tests and therapies to improve disease outcomes.
Average Trading Volume: 92,456
Technical Sentiment Signal: Hold
Current Market Cap: £108.3M
Find detailed analytics on DXRX stock on TipRanks’ Stock Analysis page.